Tokyo Tape
Sign in
← Carna Biosciences

Annual report

4572.TEDINET S100QFB8
Period2022-01-01 → 2022-12-31
Filed2023-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 137
MetricValuePeriodScopeSource row
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales
Revenue¥2.0bn2021-01-01 → 2021-12-31Cons.Net sales
Revenue¥1.1bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Revenue¥3.2bn2019-01-01 → 2019-12-31dCons.Net sales (5-year summary)
Revenue¥755m2018-01-01 → 2018-12-31dCons.Net sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31Cons.Operating income
Operating income−¥531m2021-01-01 → 2021-12-31Cons.Operating income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥523m2021-01-01 → 2021-12-31Cons.Ordinary income
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥957m2019-01-01 → 2019-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥1.3bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥532m2021-01-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥534m2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥828m2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2018-01-01 → 2018-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss
Net income−¥534m2021-01-01 → 2021-12-31Cons.Profit loss
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.4bnat 2021-12-31Cons.Assets
Total assets¥4.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total assets¥5.4bnat 2019-12-31dCons.Total assets (5-year summary)
Total assets¥1.8bnat 2018-12-31dCons.Total assets (5-year summary)
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Total liabilities¥1.1bnat 2021-12-31Cons.Liabilities
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.3bnat 2021-12-31Cons.Net assets
Net assets / equity¥3.8bnat 2020-12-31dCons.Net assets
Net assets / equity¥3.9bnat 2019-12-31dCons.Net assets (5-year summary)
Net assets / equity¥887mat 2018-12-31dCons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥3.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.8bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2020-12-31dCons.Cash and cash equivalents
Cash & equivalents¥4.9bnat 2019-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2018-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥708m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.5bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.3bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.5bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2018-01-01 → 2018-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥126m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥42m2021-01-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥70m2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41m2019-01-01 → 2019-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥58m2018-01-01 → 2018-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥367m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.1bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥724m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.1bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥688m2018-01-01 → 2018-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-90.332020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥76.052019-01-01 → 2019-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.022018-01-01 → 2018-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.512019-01-01 → 2019-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥255.04at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥323.54at 2021-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥308.05at 2020-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥329.86at 2019-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥86.83at 2018-12-31dCons.Net assets per share (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.0%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.5%at 2019-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio49.7%at 2018-12-31dCons.Equity to asset ratio (5-year summary)
ROE35.1%2019-01-01 → 2019-12-31dCons.Rate of return on equity (5-year summary)
Employees65at 2022-12-31Cons.Number of employees
Employees64at 2021-12-31Cons.Number of employees
Employees64at 2020-12-31dCons.Number of employees
Employees63at 2019-12-31dCons.Number of employees
Employees62at 2018-12-31dCons.Number of employees
Revenue¥1.2bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥1.9bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥1.0bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥3.1bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥641m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥558m2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥1.4bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥549m2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥874m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥558m2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥1.4bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥556m2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥746m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.0bnat 2022-12-31StandaloneAssets
Total assets¥5.3bnat 2021-12-31StandaloneAssets
Total assets¥4.7bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥607mat 2022-12-31StandaloneLiabilities
Total liabilities¥1.1bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥3.4bnat 2022-12-31StandaloneNet assets
Net assets / equity¥4.2bnat 2021-12-31StandaloneNet assets
Net assets / equity¥3.7bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥3.8bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥900mat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.1bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥3.6bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-103.22022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-43.832021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-91.842020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.472019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-123.852018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥67.082019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥240.82at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥314.45at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥301.39at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥323.68at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥88.07at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio84.6%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.9%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE32.0%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued14,218,300at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,313,400at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued12,407,100at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,654,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued10,139,600at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees62at 2022-12-31StandaloneNumber of employees
Employees61at 2021-12-31StandaloneNumber of employees
Employees61at 2020-12-31dStandaloneNumber of employees
Employees60at 2019-12-31dStandaloneNumber of employees
Employees58at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥3.2bn
Drug Discovery Businessreportable segmentcapex2022-01-01 → 2022-12-31¥68m
Drug Discovery Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥13m
Drug Discovery Businessreportable segmentemployeesat 2022-12-3134 pure
Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentsegment assetsat 2022-12-31¥373m
Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.7bn
Drug Discovery Support Businessreportable segmentcapex2022-01-01 → 2022-12-31¥58m
Drug Discovery Support Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥21m
Drug Discovery Support Businessreportable segmentemployeesat 2022-12-3123 pure
Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentsegment assetsat 2022-12-31¥685m
Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥453m
—segment totalcapex2022-01-01 → 2022-12-31¥126m
—segment totaldepreciation2022-01-01 → 2022-12-31¥34m
—segment totalrevenue2022-01-01 → 2022-12-31¥1.4bn
—segment totalrevenue external2022-01-01 → 2022-12-31¥1.4bn
—segment totalsegment assetsat 2022-12-31¥1.1bn
—segment totalsegment profit2022-01-01 → 2022-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥3.7bn
Drug Discovery Businessreportable segmentcapex2021-01-01 → 2021-12-31¥14m
Drug Discovery Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥5m
Drug Discovery Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥1.1bn
Drug Discovery Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥1.1bn
Drug Discovery Businessreportable segmentsegment assetsat 2021-12-31¥1.2bn
Drug Discovery Businessreportable segmentsegment profit2021-01-01 → 2021-12-31−¥820m
Drug Discovery Support Businessreportable segmentcapex2021-01-01 → 2021-12-31¥12m
Drug Discovery Support Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥15m
Drug Discovery Support Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥890m
Drug Discovery Support Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥890m
Drug Discovery Support Businessreportable segmentsegment assetsat 2021-12-31¥497m
Drug Discovery Support Businessreportable segmentsegment profit2021-01-01 → 2021-12-31¥289m
—segment totalcapex2021-01-01 → 2021-12-31¥26m
—segment totaldepreciation2021-01-01 → 2021-12-31¥19m
—segment totalrevenue2021-01-01 → 2021-12-31¥2.0bn
—segment totalrevenue external2021-01-01 → 2021-12-31¥2.0bn
—segment totalsegment assetsat 2021-12-31¥1.7bn
—segment totalsegment profit2021-01-01 → 2021-12-31−¥531m
Drug Discovery Businessreportable segmentemployeesat 2022-12-3133 pure
Drug Discovery Support Businessreportable segmentemployeesat 2022-12-3121 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,303
ItemContextValueUnit
Dividends income noiPrior1YearDuration399000JPY
Dividends income noiCurrentYearDuration411000JPY
Insurance income noiPrior1YearDuration－JPY
Insurance income noiCurrentYearDuration1957000JPY
Subsidy income noi bountyPrior1YearDuration1346000JPY
Subsidy income noi bountyCurrentYearDuration1000000JPY
Subsidy income noiPrior1YearDuration7200000JPY
Subsidy income noiCurrentYearDuration－JPY
Foreign exchange gains noiPrior1YearDuration14425000JPY
Foreign exchange gains noiCurrentYearDuration830000JPY
Other noiPrior1YearDuration837000JPY
Other noiCurrentYearDuration1243000JPY
Non operating incomePrior1YearDuration24315000JPY
Non operating incomeCurrentYearDuration5590000JPY
Interest expenses noePrior1YearDuration3925000JPY
Interest expenses noeCurrentYearDuration5310000JPY
Guarantee commission noePrior1YearDuration1336000JPY
Guarantee commission noeCurrentYearDuration977000JPY
Stock issuance cost noePrior1YearDuration3766000JPY
Stock issuance cost noeCurrentYearDuration2682000JPY
Share acquisition rights issuance costs noePrior1YearDuration5952000JPY
Share acquisition rights issuance costs noeCurrentYearDuration5501000JPY
Other noePrior1YearDuration1190000JPY
Other noeCurrentYearDuration49000JPY
Non operating expensesPrior1YearDuration16172000JPY
Non operating expensesCurrentYearDuration14522000JPY
Ordinary incomePrior1YearDuration-522992000JPY
Ordinary incomeCurrentYearDuration-1278820000JPY
Impairment loss elPrior1YearDuration9507000JPY
Impairment loss elCurrentYearDuration44578000JPY
Extraordinary lossPrior1YearDuration9507000JPY
Extraordinary lossCurrentYearDuration44578000JPY
Income before income taxesPrior1YearDuration-532499000JPY
Income before income taxesCurrentYearDuration-1323399000JPY
Income taxes currentPrior1YearDuration7780000JPY
Income taxes currentCurrentYearDuration26262000JPY
Income taxes deferredPrior1YearDuration-5805000JPY
Income taxes deferredCurrentYearDuration-122000JPY
Income taxesPrior1YearDuration1975000JPY
Income taxesCurrentYearDuration26140000JPY
Profit lossPrior1YearDuration-534474000JPY
Profit lossCurrentYearDuration-1349539000JPY
Profit loss attributable to owners of parentPrior1YearDuration-534474000JPY
Profit loss attributable to owners of parentCurrentYearDuration-1349539000JPY
Profit lossPrior1YearDuration-534474000JPY
Profit lossCurrentYearDuration-1349539000JPY
Valuation difference on available for sale securities net of tax ociPrior1YearDuration-652000JPY
Valuation difference on available for sale securities net of tax ociCurrentYearDuration-1742000JPY
Deferred gains or losses on hedges net of tax ociPrior1YearDuration7754000JPY
Deferred gains or losses on hedges net of tax ociCurrentYearDuration-5962000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-12-31pass
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-12-31pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-01-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass